#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Cardiotoxicity of AntitumorousTreatment


Authors: J. Horáček 1,2;  R. Pudil 2;  M. Tichý 1,2;  L. Jebavý 1,2;  L. Slováček 1,2
Authors‘ workplace: Katedra válečného vnitřního lékařství Vojenské lékařské akademie J. E. Purkyně, Hradec Králové 2II. interní klinika Fakultní nemocnice, Hradec Králové 1
Published in: Transfuze Hematol. dnes,, 2004, No. 2, p. 62-69.
Category:

Overview

Cardiotoxicity is a serious and relatively frequent complication in patients treated for cancer. Antitumoroustreatment can cause a number of undesirable cardiac side effects, such as arrhythmias,myocardial ischaemia, sudden death and heart failure. Cardiotoxicity can manifest anytime duringtreatment and anytime after its termination. Late cardiotoxicity of anthracyclines, which can manifestas chronic heart failure more than one year after termination of the treatment, is one of the most seriousproblems. In viewof indisputable success of antitumorous treatment recently, the issue of cardiotoxicitybecomes more and more relevant. The authors review the most frequent cardiac complications ofantitumorous treatment. They emphasize the cardiotoxicity of anthracyclines and its derivatives,because they represent the greatest risk.Furthermore, they reviewthe cardiotoxity of other cytostatics,immunomodulators, radiotherapy and cardiac complications associated with transplantation of haematopoieticcells.

Key words:
cardiotoxicity, cytostatics, immunomodulators, radiotherapy, transplantation of haematopoieticcells

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Haematology Internal medicine Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#